Sequential Infusion of Anti-CD19 and Anti-CD20 CAR-T Cells Against Relapsed and Refractory B-cell Lymphoma
Clinical trial NCT03207178 · UNKNOWN
Trial details
- NCT number
- NCT03207178
- Sponsor
- Shanghai Longyao Biotechnology Inc., Ltd.
- Status
- UNKNOWN
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-03-01
- Primary completion
- 2019-02-28
- Enrollment
- 20
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.